ARCA biopharma

Recent News & Events

MORE NEWS


	ARCA will be presenting at Bio-Europe Spring 2008 in Madrid, Spain on Wednesday, April 9, 2008 at 10:15 am in Room Berlin, Level 1.
	ARCA DISCOVERY CHANGES NAME TO ARCA BIOPHARMA TO REFLECT FOCUS ON DRUG COMMERCIALIZATION Company Appoints Randall St. Laurent as EVP of Commercial Operations
	Visit the ARCA booth at ACC 2008 – Booth #26064 March 30th – April 1st
	ARCA will be presenting at BioCentury’s Future Leaders in the Biotech Industry March 27th, 2008 Breakout Room 306: 3:55PM – 4:55PM
	2/17/08 - McClatchy-Tribune Regional News AHEAD OF THE CURVE: LabCorp enters brave new world of genetic-based testing
	1/04/08 - ARCA Discovery, Inc. to present at 26th annual JPMorgan healthcare conference on January 8, 2008
	11/09/07 - OTHER NEWS TO NOTE. BIOWORLD Today

About

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.

Science

ARCA is currently developing bucindolol for the treatment of heart failure. ARCA anticipates submitting an application with the FDA for approval of bucindolol in 2008. Bucindolol will have market exclusivity through 2024.